These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24378455)

  • 21. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 22. Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: ion specific chelation.
    Kruck TP; McLachlan DR
    Prog Clin Biol Res; 1989; 317():1155-67. PubMed ID: 2690090
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of iron overload with a disposable multi-day delivery system.
    Paolo C; Francesco S; Sergio A
    Am J Hematol; 1996 Jan; 51(1):95. PubMed ID: 8571948
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):287-95. PubMed ID: 19814674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined iron chelation therapy.
    Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
    Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.
    Osborne RH; De Abreu Lourenço R; Dalton A; Houltram J; Dowton D; Joshua DE; Lindeman R; Ho PJ
    Value Health; 2007; 10(6):451-6. PubMed ID: 17970927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron: not a benign therapeutic drug.
    Madiwale T; Liebelt E
    Curr Opin Pediatr; 2006 Apr; 18(2):174-9. PubMed ID: 16601499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alzheimer's disease, metal ions and metal homeostatic therapy.
    Zatta P; Drago D; Bolognin S; Sensi SL
    Trends Pharmacol Sci; 2009 Jul; 30(7):346-55. PubMed ID: 19540003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chelation of bismuth by combining desferrioxamine and deferiprone in rats.
    Tubafard S; Fatemi SJ
    Toxicol Ind Health; 2008 May; 24(4):235-40. PubMed ID: 19022876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
    Kontoghiorghes GJ; Efstathiou A; Kleanthous M; Michaelides Y; Kolnagou A
    Hemoglobin; 2009; 33(5):386-97. PubMed ID: 19814684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Desferal treatment of aluminum poisoning; effect on serum concentrations of aluminum (Al), iron (Fe) and copper (Cu)].
    Günther K; Winnefeld K; Stein G; Sperschneider H; Schröter H; Fünfstück R
    Z Urol Nephrol; 1986 Oct; 79(10):569-76. PubMed ID: 3811645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
    Yokel RA
    J Toxicol Environ Health; 1994 Feb; 41(2):131-74. PubMed ID: 8301696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges associated with metal chelation therapy in Alzheimer's disease.
    Hegde ML; Bharathi P; Suram A; Venugopal C; Jagannathan R; Poddar P; Srinivas P; Sambamurti K; Rao KJ; Scancar J; Messori L; Zecca L; Zatta P
    J Alzheimers Dis; 2009; 17(3):457-68. PubMed ID: 19363258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute toxicity in five dogs after ingestion of a commercial snail and slug bait containing iron EDTA.
    Haldane SL; Davis RM
    Aust Vet J; 2009 Jul; 87(7):284-6. PubMed ID: 19573155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.